Previsioni

Acquista	4
Mantieni	0
Vendi	0

Notizie Vai al feed delle notizie

Sonnet BioTherapeutics reports quarterly loss of $0.79 per share

Sonnet BioTherapeutics reported a loss per share of $0.79 for the most recent quarter (prior year: -$4.81). For the full year the company posted a loss per share of $3.95 after -$11.35 in the prior year, and annual revenue rose to $1.00 million (prior year: $0.02 million). Analysts had expected a loss of $3.46 per share for the year and revenue of $1.00 million. » Altro su finanzen.net
Sonnet BioTherapeutics signs employment contract with interim CEO Raghu Rao and announces merger and delisting risk

Sonnet BioTherapeutics has signed an employment contract with interim CEO Raghu Rao, which includes an annual salary of $400,000 and performance-based bonuses. The company also announced a significant merger to form Hyperliquid Strategies Inc., which would transform Sonnet into a crypto treasury with HYPE tokens and cash valued at $888 million. At the same time, Sonnet received a delisting notice from Nasdaq for failing to meet equity requirements. » Altro su de.investing.com
Sonnet BioTherapeutics surges after $888 million crypto deal

Shares of Sonnet BioTherapeutics jumped 290% following the announcement of a $888 million merger. The company will transform into a crypto treasury specializing in HYPE tokens and operate as a subsidiary of Hyperliquid Strategies. Leading crypto investors and new executives are involved in the transaction, which is expected to close in the second half of the year. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Sonnet Biotherapeutics ha registrato ricavi pari a 0,00€ e un utile netto di −4,84M€

(EUR)	set 2025	YoY
Ricavi	0,00	-
Utile lordo	+792,76k	-
Utile netto	−4,84M	-
EBITDA	+9,27M	-

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+7,24M€
Numero di azioni	6,69M
Massimo/minimo a 52 settimane	+16,57€ - +0,93€
Dividendi	No
Beta	1,47
Rapporto P/E	−0,53
Rapporto PEG	−0,01
Rapporto P/B	+0,48
Rapporto P/S	0,00

Profilo aziendale

Sonnet BioTherapeutics Holdings, Inc. ist ein auf Onkologie spezialisiertes Biotechnologieunternehmen in der klinischen Phase und entwickelt eine Plattform für biologische Arzneimittel mit einfacher oder bispezifischer Wirkung. Das Unternehmen entwickelt eine vollständig humane Albuminbindungs-Technologie, bei der ein menschliches Einzelketten-Antikörperfragment verwendet wird, das sich an menschliches Serumalbumin bindet und per Anhalter zu den Zielgeweben transportiert wird. Der führende Kandidat ist SON-1010, eine vollständig humane Version von Interleukin 12 für die Behandlung von nicht-kleinzelligem Lungenkrebs sowie von Kopf- und Halskrebs. Das Unternehmen entwickelt außerdem SON-080, eine vollständig humane Version von Interleukin 6 zur Behandlung der durch Chemotherapie verursachten peripheren Neuropathie und der diabetischen peripheren Neuropathie. Es hat eine Lizenzvereinbarung mit New Life Therapeutics PTE, LTD. zur Entwicklung und Vermarktung von pharmazeutischen Präparaten, die ein spezifisches rekombinantes menschliches Interleukin 6 enthalten. Sonnet BioTherapeutics Holdings, Inc. hat seinen Sitz in Princeton, New Jersey.

Nome	Sonnet Biotherapeutics
CEO	Raghu Rao
Sede centrale	Princeton, nj Stati Uniti
Sito web	sonnetbio.com
Settore	Materiali
Industria	Prodotti chimici
Quotazione in borsa	31/10/2006
Dipendenti	13